drugset / Trial / NCT01185704
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized open-label study to compare between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted reproductive technology (ART).
Timeline
- Start
- 2008-11
- Primary completion
- 2011-10
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetrorelix | Other / unclassified | 0.25 mg | Subcutaneous |
| Background | Ovidrel | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Background | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 75 iu | Subcutaneous |
| Background | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 187.5 iu | Subcutaneous |